China Medical System Holdings Past Earnings Performance
Past criteria checks 2/6
China Medical System Holdings has been growing earnings at an average annual rate of 4%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 7.4% per year. China Medical System Holdings's return on equity is 8.6%, and it has net margins of 19.8%.
Key information
4.0%
Earnings growth rate
4.3%
EPS growth rate
Pharmaceuticals Industry Growth | 5.6% |
Revenue growth rate | 7.4% |
Return on equity | 8.6% |
Net Margin | 19.8% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Earnings Tell The Story For China Medical System Holdings Limited (HKG:867) As Its Stock Soars 26%
Sep 30Little Excitement Around China Medical System Holdings Limited's (HKG:867) Earnings
Jul 15An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 20% Undervalued
May 22China Medical System Holdings (HKG:867) Is Paying Out Less In Dividends Than Last Year
May 03We Think Shareholders May Want To Consider A Review Of China Medical System Holdings Limited's (HKG:867) CEO Compensation Package
May 02China Medical System Holdings' (HKG:867) Shareholders Will Receive A Smaller Dividend Than Last Year
Apr 19China Medical System Holdings (HKG:867) Is Paying Out Less In Dividends Than Last Year
Mar 29Not Many Are Piling Into China Medical System Holdings Limited (HKG:867) Stock Yet As It Plummets 35%
Mar 28China Medical System Holdings Limited's (HKG:867) Share Price Not Quite Adding Up
Dec 21Is China Medical System Holdings (HKG:867) A Risky Investment?
Dec 04If EPS Growth Is Important To You, China Medical System Holdings (HKG:867) Presents An Opportunity
Nov 15China Medical System Holdings (HKG:867) Will Pay A Larger Dividend Than Last Year At CN¥0.342
Aug 31China Medical System Holdings (HKG:867) Could Easily Take On More Debt
Aug 30Here's Why We Think China Medical System Holdings (HKG:867) Might Deserve Your Attention Today
Aug 07We Think China Medical System Holdings (HKG:867) Can Manage Its Debt With Ease
May 14Does China Medical System Holdings (HKG:867) Deserve A Spot On Your Watchlist?
Apr 26An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 47% Undervalued
Feb 05China Medical System Holdings (HKG:867) Seems To Use Debt Rather Sparingly
Dec 26If EPS Growth Is Important To You, China Medical System Holdings (HKG:867) Presents An Opportunity
Dec 08Is China Medical System Holdings (HKG:867) Using Too Much Debt?
Sep 14China Medical System Holdings (HKG:867) Is Paying Out A Larger Dividend Than Last Year
Aug 25Do China Medical System Holdings' (HKG:867) Earnings Warrant Your Attention?
Aug 15An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 49% Undervalued
Jul 08Should You Be Adding China Medical System Holdings (HKG:867) To Your Watchlist Today?
May 16Does China Medical System Holdings (HKG:867) Have A Healthy Balance Sheet?
Apr 10China Medical System Holdings (HKG:867) Is Increasing Its Dividend To HK$0.28
Mar 22If You Like EPS Growth Then Check Out China Medical System Holdings (HKG:867) Before It's Too Late
Feb 09Does China Medical System Holdings (HKG:867) Have A Healthy Balance Sheet?
Dec 25Should You Be Adding China Medical System Holdings (HKG:867) To Your Watchlist Today?
Nov 10China Medical System Holdings (HKG:867) Could Easily Take On More Debt
Sep 25China Medical System Holdings' (HKG:867) Dividend Will Be Increased To HK$0.32
Aug 26Here's Why We Think China Medical System Holdings (HKG:867) Is Well Worth Watching
Jul 30An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 33% Undervalued
Jun 27Revenue & Expenses Breakdown
How China Medical System Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 7,014 | 1,390 | 3,272 | 225 |
31 Mar 24 | 7,514 | 1,896 | 3,220 | 210 |
31 Dec 23 | 8,013 | 2,401 | 3,168 | 195 |
30 Sep 23 | 8,663 | 2,891 | 3,313 | 170 |
30 Jun 23 | 9,313 | 3,381 | 3,457 | 146 |
31 Mar 23 | 9,232 | 3,320 | 3,408 | 136 |
31 Dec 22 | 9,150 | 3,259 | 3,358 | 125 |
30 Sep 22 | 9,046 | 3,224 | 3,347 | 129 |
30 Jun 22 | 8,942 | 3,189 | 3,336 | 133 |
31 Mar 22 | 8,640 | 3,103 | 3,159 | 124 |
31 Dec 21 | 8,337 | 3,017 | 2,981 | 115 |
30 Sep 21 | 8,009 | 2,948 | 2,782 | 94 |
30 Jun 21 | 7,681 | 2,878 | 2,583 | 73 |
31 Mar 21 | 7,313 | 2,704 | 2,444 | 70 |
31 Dec 20 | 6,946 | 2,530 | 2,304 | 67 |
30 Sep 20 | 6,582 | 2,300 | 2,198 | 63 |
30 Jun 20 | 6,217 | 2,070 | 2,092 | 60 |
31 Mar 20 | 6,145 | 2,015 | 2,119 | 53 |
31 Dec 19 | 6,074 | 1,961 | 2,145 | 45 |
30 Sep 19 | 5,908 | 2,011 | 2,103 | 30 |
30 Jun 19 | 5,743 | 2,062 | 2,060 | 15 |
31 Mar 19 | 5,588 | 1,956 | 1,988 | 8 |
31 Dec 18 | 5,433 | 1,850 | 1,916 | 0 |
30 Sep 18 | 5,375 | 1,839 | 1,829 | 0 |
30 Jun 18 | 5,317 | 1,827 | 1,743 | 0 |
31 Mar 18 | 5,333 | 1,751 | 1,674 | 0 |
31 Dec 17 | 5,349 | 1,675 | 1,604 | 0 |
30 Sep 17 | 5,379 | 1,601 | 1,566 | 0 |
30 Jun 17 | 5,410 | 1,527 | 1,529 | 0 |
31 Mar 17 | 5,155 | 1,452 | 1,462 | 0 |
31 Dec 16 | 4,901 | 1,376 | 1,395 | 0 |
30 Sep 16 | 4,477 | 1,265 | 1,259 | 0 |
30 Jun 16 | 4,054 | 1,155 | 1,123 | 0 |
31 Mar 16 | 3,804 | 1,075 | 1,065 | 0 |
31 Dec 15 | 3,553 | 996 | 1,007 | 0 |
30 Sep 15 | 3,404 | 1,062 | 957 | 0 |
30 Jun 15 | 3,255 | 1,128 | 908 | 0 |
31 Mar 15 | 3,100 | 1,087 | 845 | 0 |
31 Dec 14 | 2,945 | 1,046 | 783 | 0 |
30 Sep 14 | 2,760 | 890 | 729 | 0 |
30 Jun 14 | 2,575 | 734 | 676 | 0 |
31 Mar 14 | 2,412 | 685 | 644 | 0 |
31 Dec 13 | 2,249 | 636 | 613 | 0 |
Quality Earnings: 867 has high quality earnings.
Growing Profit Margin: 867's current net profit margins (19.8%) are lower than last year (36.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 867's earnings have grown by 4% per year over the past 5 years.
Accelerating Growth: 867's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 867 had negative earnings growth (-58.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.4%).
Return on Equity
High ROE: 867's Return on Equity (8.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/21 04:31 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
China Medical System Holdings Limited is covered by 34 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jessica Li | BofA Global Research |
Lok Kwan Chiu | CCB International Securities Limited |
Harry He | China Galaxy International Securities (Hong Kong) |